U.S. Markets closed

Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
32.95-0.41 (-1.23%)
At close: 4:00PM EDT

32.93 -0.02 (-0.06%)
After hours: 6:44PM EDT

People also watch
MRKJNJJPMINTCGE
Full screen
Previous Close33.36
Open33.29
Bid32.86 x 100
Ask32.93 x 500
Day's Range32.95 - 33.45
52 Week Range29.83 - 35.38
Volume14,858,462
Avg. Volume18,956,709
Market Cap196.64B
Beta1.05
PE Ratio (TTM)27.74
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.28 (3.84%)
Ex-Dividend Date2017-08-02
1y Target EstN/A
Trade prices are not sourced from all markets
  • FDA OKs Pfizer drug for rare, fast-killing type of leukemia
    Associated Press1 hour ago

    FDA OKs Pfizer drug for rare, fast-killing type of leukemia

    TRENTON, N.J. (AP) — The Food and Drug Administration has approved a new medicine for use against a rare, rapidly progressing blood cancer after other treatments have failed.

  • Reuters3 hours ago

    FDA approves Pfizer's drug for rare blood cancer

    The U.S. Food and Drug Administration (FDA) said on Thursday it approved Pfizer Inc's rare blood cancer drug, Besponsa, with a boxed warning. Besponsa was approved to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

  • Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
    Zacks9 hours ago

    Can Pfizer Bank on New Immunotherapy Bavencio for Growth?

    Pfizer, Inc.'s (PFE) newly approved anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant top-line driver for this New York-based pharma giant.